Because Keap1 methylation is accredited to inhibiting Nrf2 activation and is found in higher amounts of cataract patients, drugs increasing methylation or decreasing demethylation are being evaluated for their aptitude in restricting cataract pathology [123, 124, 126]. Here, KEAP1 is linked to cataract.